Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-08-13 4:12 pm Purchase | 2026-06-30 | 13G | LEXEO THERAPEUTICS INC LXEO | Affinity Asset Advisors, LLC | 6,674,913 8.400% | 1,457,253 (+27.93%) | Filing History |
| 2026-08-13 4:11 pm Purchase | 2026-06-30 | 13G | EQUILLIUM INC EQ | Affinity Asset Advisors, LLC | 4,100,000 6.500% | 4,100,000 (New Position) | Filing History |
| 2026-08-13 4:10 pm Purchase | 2026-06-30 | 13G | AMANAT ACQUISITION CORP USD CL AMAN | Affinity Asset Advisors, LLC | 375,000 5.000% | 375,000 (New Position) | Filing History |
| 2026-08-13 4:09 pm Purchase | 2026-06-30 | 13G | FIRST TRACKS BIOTHERAPEUTICS I TRAX | Affinity Asset Advisors, LLC | 2,032,012 5.800% | 2,032,012 (New Position) | Filing History |
| 2026-08-13 4:08 pm Purchase | 2026-06-30 | 13G | FORTE BIOSCIENCES INC FBRX | Affinity Asset Advisors, LLC | 1,145,391 5.600% | 133,501 (+13.19%) | Filing History |
| 2026-08-13 4:07 pm Sale | 2026-06-30 | 13G | OVID THERAPEUTICS INC OVID | Affinity Asset Advisors, LLC | 15,143,728 7.900% | -491,756 (-3.15%) | Filing History |
| 2026-08-13 4:06 pm Purchase | 2026-06-30 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Affinity Asset Advisors, LLC | 2,900,000 5.500% | 1,559,160 (+116.28%) | Filing History |
| 2026-08-13 4:05 pm Purchase | 2026-06-30 | 13G | IBIO INC PAR $0.001 IBIO | Affinity Asset Advisors, LLC | 5,068,882 9.990% | 1,579,834 (+45.28%) | Filing History |
| 2026-08-13 4:05 pm Sale | 2026-06-30 | 13G | NEXTCURE INC NXTC | Affinity Asset Advisors, LLC | 274,073 6.400% | -74,534 (-21.38%) | Filing History |
| 2026-05-14 4:17 pm Purchase | 2026-03-31 | 13G | OVID THERAPEUTICS INC OVID | Affinity Asset Advisors, LLC | 15,635,484 9.100% | 3,486,318 (+28.70%) | Filing History |
| 2026-05-14 4:15 pm Purchase | 2026-03-31 | 13G | FORTE BIOSCIENCES INC FBRX | Affinity Asset Advisors, LLC | 1,011,890 7.300% | 176,926 (+21.19%) | Filing History |
| 2026-05-14 4:14 pm Sale | 2026-03-31 | 13G | VENTYX BIOSCIENCES INC VTYX | Affinity Asset Advisors, LLC | 0 0.000% | -6,465,041 (Position Closed) | Filing History |
| 2026-05-14 4:13 pm Purchase | 2026-03-31 | 13G | SUTRO BIOPHARMA INC STRO | Affinity Asset Advisors, LLC | 1,069,519 6.500% | 321,137 (+42.91%) | Filing History |
| 2026-05-14 4:11 pm Purchase | 2026-03-31 | 13G | IBIO INC PAR $0.001 IBIO | Affinity Asset Advisors, LLC | 3,489,048 9.990% | 1,087,432 (+45.28%) | Filing History |
| 2026-05-14 4:09 pm Purchase | 2026-03-31 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Affinity Asset Advisors, LLC | 1,340,840 5.500% | 289,786 (+27.57%) | Filing History |
| 2026-05-14 4:08 pm Purchase | 2026-03-31 | 13G | HELIX ACQUISITION CORP. III US HLXC | Affinity Asset Advisors, LLC | 1,250,000 7.000% | 1,250,000 (New Position) | Filing History |
| 2026-05-14 4:05 pm Purchase | 2026-03-31 | 13G | KARYOPHARM THERAPEUTICS INC CO KPTI | Affinity Asset Advisors, LLC | 2,073,517 8.600% | 360,425 (+21.04%) | Filing History |
| 2026-01-29 9:33 pm Purchase | 2026-01-22 | 13G | NEXTCURE INC NXTC | Affinity Asset Advisors, LLC | 348,607 9.990% | 156,725 (+81.68%) | Filing History |
| 2026-01-29 9:32 pm Purchase | 2026-01-22 | 13G | KARYOPHARM THERAPEUTICS INC CO KPTI | Affinity Asset Advisors, LLC | 1,713,092 8.600% | 1,048,868 (+157.91%) | Filing History |
| 2026-01-29 9:29 pm Purchase | 2026-01-22 | 13G | IBIO INC PAR $0.001 IBIO | Affinity Asset Advisors, LLC | 2,401,616 9.990% | 220,196 (+10.09%) | Filing History |